Automated analysis of acute myeloid leukemia minimal residual disease using a support vector machine
Metrics: PDF 628 views | HTML 835 views | ?
Wanmao Ni1, Beili Hu2, Cuiping Zheng3, Yin Tong4, Lei Wang1, Qing-qing Li1, Xiangmin Tong1, Yong Han1
1Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People’s Hospital, Hangzhou, Zhejiang, P. R. China
2Medical of College, Zhejiang University, Hangzhou, Zhejiang, P. R. China
3The Center Hospital of Wenzhou, Wenzhou, Zhejiang, P. R. China
4Department of Hematology, Shanghai General Hospital, Shanghai, P. R. China
Xiangmin Tong, email: email@example.com
Yong Han, email: firstname.lastname@example.org
Keywords: flow cytometry, immunophenotyping, support vector machine, acute myeloid leukemia, minimal residual disease
Received: July 04, 2016 Accepted: September 29, 2016 Published: October 04, 2016
We investigated the ability of support vector machines (SVM) to analyze minimal residual disease (MRD) in flow cytometry data from patients with acute myeloid leukemia (AML) automatically, objectively and standardly. The initial disease data and MRD review data in the form of 159 flow cytometry standard 3.0 files from 36 CD7-positive AML patients in whom MRD was detected more than once were exported. SVM was used for training with setting the initial disease data to 1 as the flag and setting 15 healthy persons to set 0 as the flag. Based on the two training groups, parameters were optimized, and a predictive model was built to analyze MRD data from each patient. The automated analysis results from the SVM model were compared to those obtained through conventional analysis to determine reliability. Automated analysis results based on the model did not differ from and were correlated with results obtained through conventional analysis (correlation coefficient c = 0.986, P > 0.05). Thus the SVM model could potentially be used to analyze flow cytometry-based AML MRD data automatically, objectively, and in a standardized manner.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.